Andrew Berens analyst LEERINK

Currently out of the existing stock ratings of Andrew Berens, 151 are a BUY (70.89%), 45 are a HOLD (21.13%), 17 are a SELL (7.98%).

Andrew Berens

Work Performance Price Targets & Ratings Chart

Analyst Andrew Berens works at LEERINK with a stock forecast success ratio of 45.84% fulfilled within 170.29 days on average. Previously, Andrew Berens worked at MORGAN STANLEY.

Andrew Berens’s has documented 414 price targets and ratings displayed on 38 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on INCY, yte at 13-Dec-2023.

Wall Street Analyst Andrew Berens

Analyst best performing recommendations are on ELEV (ELEVATION ONCOLOGY).
The best stock recommendation documented was for ELEV (ELEVATION ONCOLOGY) at 1/9/2023. The price target of $1 was fulfilled within 3 days with a profit of $0.2 (25%) receiving and performance score of 83.33.

Average potential price target upside

AGIO Agios Pharm AVEO AVEO Pharmaceuticals BGNE BeiGene Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EPZM Epizyme FMTX Forma Therapeutics Holdings GPRE Green Plains Renewable Energy INCY yte MRTX Mirati Ther SGEN Seagen ZNTL Zentalis Pharmaceuticals Llc ZYME Zymeworks . Common Stock AZN AstraZeneca PLC ADR CLVS Clovis Oncology GILD Gilead Sciences GWPH GW Pharmaceuticals plc HOOK Hookipa Pharma ARVN Arvinas GBT Global Blood Therapeutics ICPT Intercept Pharmaceuticals MRUS Merus BV OCUL Ocular Therapeutix RLYP Relypsa CGEM Cullinan Oncology LLC CMPX Compass Therapeutics . GLUE Monte Rosa Therapeutics TNGX Tango Therapeutics TPTX Turning Point Therapeutics NRIX Nurix Therapeutics  COGT Cogent Biosciences ELEV Elevation Oncology AURA Aura Biosciences RMTI Rockwell Medical THRX Theseus Pharmaceuticals CTIC CTi Biopharma Corp REGN Regeneron Pharmaceuticals VIRX Viracta Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

28

$1.2 (4.48%)

32

3 months 20 days ago

4/6 (66.67%)

$5.51 (24.50%)

145

Hold

32

$5.2 (19.40%)

33

6 months 16 days ago

0/2 (0%)

$6.45 (25.24%)

Buy

42

$15.2 (56.72%)

67

7 months 27 days ago

5/12 (41.67%)

$13.87 (49.31%)

213

Buy

38

$11.2 (41.79%)

40

7 months 27 days ago

0/4 (0%)

$9.87 (35.09%)

Buy

37

$10.2 (38.06%)

33

1 years 6 months 18 days ago

6/11 (54.55%)

$7.26 (24.41%)

69

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Andrew Berens is most bullish on?

Potential upside of $17.09 has been obtained for INCY (YTE)

Which stock is Andrew Berens is most reserved on?

Potential downside of -$0.7 has been obtained for MRTX (MIRATI THER)

What Year was the first public recommendation made by Andrew Berens?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?